Botox Therapy for Ischemic Digits

@article{Neumeister2009BotoxTF,
  title={Botox Therapy for Ischemic Digits},
  author={Michael W. Neumeister and Christopher B Chambers and Margo S Herron and Kelli N Webb and Joel Wietfeldt and Jessica Nicole Gillespie and Rueben A. Bueno and Carisa Miller Cooney},
  journal={Plastic and Reconstructive Surgery},
  year={2009},
  volume={124},
  pages={191-201}
}
Background: Treating patients with Raynaud's phenomenon who have chronic pain and ulcerations is extremely challenging. Unrelenting pain can lead to dysfunction and disuse, rendering the patient debilitated and/or chronically depressed. Pharmacologic vasodilators and surgical sympathectomies offer variable benefits. Outcomes of symptomatic patients treated with botulinum toxin type A (Botox) injections for Raynaud's phenomenon are presented. Methods: A retrospective study focused on patient… Expand
View on Wolters Kluwer
ncbi.nlm.nih.gov
100 Citations
Highly Influential Citations
4
Background Citations
11
Methods Citations
1
Results Citations
3

Paper Mentions

Interventional Clinical Trial
Botulinum Toxin Type A for Neuroma Pain
The purpose of this study is to determine if botulinum toxin type A (Btx-A) is an effective treatment for painful neuromas. The ideal therapy for painful neuromas would be effective… Expand
ConditionsNeuroma
InterventionDrug, Other
Southern Illinois University
January 2015 - September 2017
Interventional Clinical Trial
A Two-Part Study of BOTOX® Therapy for Ischemic Digits
Treating patients with Raynaud's phenomenon who have chronic pain and ulcerations is extremely challenging. Published reports and our previous work support our hypothesis that… Expand
ConditionsRaynaud's Disease
InterventionDrug
Southern Illinois University
May 2011 - July 2016
Blog Post
Cold hands: Could it be Raynaud’s?
Harvard Health Blog
3 December 2014
Blog Post
Cold hands: Could it be Raynaud’s?
Harvard Health Blog
3 December 2014

100 Citations

Citation Type

Citation Type

Botulinum toxin type A in the treatment of Raynaud's phenomenon.
TLDR
Botulinum toxin appears to improve perfusion of the hand after direct injection around the neurovascular bundles and further investigations are warranted to identify the exact mode of action in relieving vasospasm and alleviating pain. Expand
Botulinum Toxin A Treatment for Primary and Secondary Raynaud's Phenomenon in Teenagers.
TLDR
BTX injection is a simple, noninvasive, and cost-effective treatment alternative, offering an important nonsurgical therapeutic option for the pediatric population, and could also help optimize the dose of other treatments used in these patients. Expand
Botulinum toxin for Raynaud's phenomenon: an useffull but seldom reminded therapy for severe cases
Introduction: Raynaud's phenomenon (RP) is an exaggerated physiological response of the extremity vessels, mainly to cold and stress. Patients refractory to clinical treatment or intolerant to its… Expand
Targeted high concentration botulinum toxin A injections in patients with Raynaud’s phenomenon: a retrospective single-centre experience
TLDR
It is shown that targeted low volume higher concentration Botulinum toxin A injections are effective in treating Raynaud’s phenomenon and the importance of toxin concentration and injection sites is explored. Expand
Botulinum A Toxin Injection as an Adjuvant Wintering Therapy in Patients with Raynaud's Syndrome
TLDR
Botulinum A toxin injection in patients with secondary Raynaud’s syndrome before the winter season may provide substantial improvements in pain and ulceration, as the pain increases during the cold season. Expand
The Effects of Botulinum Toxin A on Pain in Ischemic Vasospasm.
TLDR
Botulinum toxin type A administration can result in rapid and sustained pain relief for several months with a reduction in opioid prescriptions and improve patient-reported disability for 6 months. Expand
A prospective study of the use of botulinum toxin injections in the treatment of Raynaud’s syndrome associated with scleroderma
TLDR
Botulinum toxin is found to be an effective treatment for Raynaud’s syndrome secondary to scleroderma and objective parameters were statistically significantly improved; however, subjective outcomes only showed a trend. Expand
Optimisation of botulinum toxin type a treatment for the management of Raynaud’s phenomenon using a dorsal approach: a prospective case series
TLDR
Dorsal botulinum toxin type A injections can improve the symptoms of secondary Raynaud’s phenomenon and hand function for approximately 3 months and reduces the number of RP. Expand
Ultrasound‐guided digital sympathectomy using botulinum toxin
TLDR
An ultrasound-guided technique is described that may improve toxin delivery and reduce the risk of complications in patients with Raynaud’s disease by performing digital sympathectomy by injection of botulinum toxin around involved neurovascular bundles. Expand
Recent advances for the management of Raynaud phenomenon using botulinum neurotoxin A.
TLDR
The potential treatment of Raynaud phenomenon using botulinum neurotoxin A (BoNT-A) is reviewed, which results in digital ischemia, which can preispose the patient to occlusive disease with ulcers nd gangrene. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 74 REFERENCES
Management of Vasospastic Disorders with Botulinum Toxin A
TLDR
Because of the complexity of surgical digital artery sympathectomy along with its associated high risk of persistent symptoms, the authors conclude that the therapeutic use of botulinum toxin A injections represents an attractive alternative therapy. Expand
Efficacy of Botulinum Toxin Type A in the Relief of Carpal Tunnel Syndrome
TLDR
The data suggest long-lasting antinociceptive effects of botulinum toxin A rather than electrophysiological restoration in patients with CTS, which may have been confounded by the placebo effect of intracarpal injection. Expand
Surgery for ischemic pain and Raynaud's' phenomenon in scleroderma: A description of treatment protocol and evaluation of results
TLDR
PS in combination with radial and ulnar arteriolysis appears to be efficacious at both early and long‐term review, and the treatment protocol in this complex population of patients is reviewed. Expand
Peripheral Sympathectomy for Raynaud's Phenomenon: A Salvage Procedure
TLDR
As a salvage procedure for Raynaud's phenomenon recalcitrant to conservative treatment, peripheral sympathectomy improves perfusion to ischemic digits and enables amputation to be avoided. Expand
Digital Sympathectomy of the Lower Extremity: A Novel Approach to Toe Salvage
TLDR
Early experience with the novel use of digital sympathectomy of the toe is reported, citing the use of this technique as a treatment or salvage option for the ischemic changes associated with scleroderma involving the toes. Expand
Botulinum Toxin Type B in Piriformis Syndrome
  • Amy M Lang
  • Medicine
  • American journal of physical medicine & rehabilitation
  • 2004
TLDR
Findings suggest the possibility that botulinum toxin type B may be of potential benefit in the treatment of pain attributed to piriformis syndrome. Expand
Periarterial sympathectomy in scleroderma patients: intermediate-term follow-up.
TLDR
The use of periarterial sympathectomy (PAS) to manage chronic digital ischemia caused by scleroderma remains controversial by examining microvascular physiology, health-related quality of life, and patient satisfaction. Expand
Botulinum toxin a has antinociceptive effects in treating interstitial cystitis.
TLDR
The results suggest that BTX-A has an antinociceptive effect on bladder afferent pathways in patients with IC, producing both symptomatic and functional (ie, urodynamic) improvements. Expand
Treatment of lateral epicondylitis with botulinum toxin: a randomized, double-blind, placebo-controlled trial.
TLDR
Botulinum toxin injection may improve pain over a 3-month period in some patients with lateral epicondylitis, but injections may be associated with digit paresis and weakness of finger extension. Expand
Botulinum toxin in the treatment of Raynaud's phenomenon: a pilot study
TLDR
As a pilot to a randomized, double-blinded, placebocontrolled trial, primary and secondary RP patients with intradigital BTX-A injections with clear beneficial effects on vasoconstriction and vasodilation were treated. Expand
...
1
2
3
4
5
...